Animal C2 presenting an abrupt EAE had elevated anti-MOG IgG1 and animal C3 with mild 166 EAE had the lowest titer of anti-MOG IgG1. These observations are consistent with the severity 167 of disease being correlated to the level of anti-MOG IgG1. However, treated animals T1 and T2 168 also had high levels of anti-MOG IgG1 at 35 dpi and thereafter, but resolutely remained 169 asymptomatic (figure 3B). This indicates that the production of anti-MOG immunoglobulin was 170 not modulated by anti-DC-ASGPR-MOG and that high levels of circulating anti-MOG IgG1 is 171 not sufficient to trigger clinical EAE. This points out that the pathogenic factor suppressed by the 172 treatment is not related to anti-MOG IgG1. 173
174

Increased neutrophils and drops of lymphocytes at disease onset 175
We had previously noticed that EAE onset and progression in cynomolgus macaques are 176 correlated with a dramatic surge of circulating neutrophils and a concomitant drop of 177 lymphocytes resulting in a rising neutrophil to lymphocytes ratio (NLR) (our unpublished 178 results). Here, we also observed that severe EAE in control animals was associated with an 179 abrupt increase of circulating neutrophils and a concomitant drop of circulating lymphocytes, 180 starting at onset of disease leading to a steep NLR increase (C1 and C2, fig. S2 ). In the control9 animal C3 with milder EAE the transient clinical signs detected at 24-29 dpi was also associated 182 to weak peaks of NLR. In the 3 animals treated with the anti-DC-ASGPR-MOG, although 1 of 183 them had a small cortical lesion at MRI, blood leukocytes remained at base level suggesting that 184 the treatment prevented neutrophils outburst and lymphocytes decline in the blood ( fig. S2) . 185
These findings point to a pathogenic role of neutrophils, as also noticed in rhesus macaque EAE 186 (Dunham et al, 2017) . 
Cytokine levels in plasma 209
We measured plasma levels of 15 cytokines at different time points in treated and control 210 monkeys and in 4 naïve animals. A heatmap revealed 4 groups, which from right to left are 211 ordered from lower to higher content of cytokines ( figure 5A and fig. S4 ); Group I encloses 212 only treated animals at 21 and 28 dpi depicting a "disease solving" profile with particularly low 213 levels of TGFb2 and higher levels of IL-10. Group II, is the most heterogeneous and includes all 214 treated and control animals at 7 dpi, as well as some animals of either group at 21 or 28 dpi but 215 no naïve animals, pointing at a "disease incubation" pattern with a significant decrease of TGFb1 216 (p=0.0002), TGFb2 (p=0.00002) and IL8 (p=0.01) as compared to naïve animals ( Figure 5B) . 217
Group III aggregates the naïve macaques, the 3 treated animals remaining healthy at 35 dpi (1 218 week after 1 st boost with rhMOG/IFA) and control C3 at 35 dpi, in remission from a mild EAE. 219
This group then relates to a "healthy pattern" of cytokines with "restored" levels of IL8, TGFb1 220 and TGFb2, and treated macaques displaying even higher levels of TGFb1 (p=0.002), TGFb2 221 (p=0.006) and IL8 (p=0.03) than naïve animals ( Figure 5C ). Group IV gathers only animals 222 treated with anti-DC-ASGPR-PSA at onset or peak of EAE with decreased TGFb1 (p=0.008), 223 TGFb2 (p=0.015) but not IL8 (p=0.05) as compared to naïve animals and with concomitant 224 increased levels of pro-inflammatory cytokines (see below). These comparisons reveal that EAE 225 incubation and onset are associated to a drop of systemic levels of TGFb1, TGFb2 and IL8 as 226 well as to an increase in pro-inflammatory cytokines, and that the treatment restores TGFb1, 227
TGFb2 and IL8 expression to physiological levels or above and prevents burst of pro- TGFb2 after reimmunization at 35 dpi ( fig. S3) . In fact, comparing cytokine levels between the 234 two groups shows that the 3 controls, but not treated animals, had increased levels of the pro-235 inflammatory cytokines IL-1b (p=0.01), IFNg (p=6x10 -4 ) and TNFa (p=0.01) at disease onset 236 (35 dpi) as compared to earlier time points. Instead, TGFb1 (p=3x10 -7 ) TGFb2 (p=3x10 -5 ) and 237 IL-8 (p=9x10 -5 ), were notably increased in treated animals at 35 dpi as compared to earlier time 238 points, which was not the case in controls (figure 6). 239 Interestingly, at 28 and 35 dpi, the resilient animal C3, which had earlier developed a mild form 240 of EAE, displayed a peculiar intermediary pattern of cytokines to that measured in animals with 241 full-blown EAE and in treated animals. It combined both patterns of pro-and anti-inflammatory 242 cytokines, suggesting that at some point the latter were sufficient to control the disease 243 progression ( fig. S3) . 
Study Design and Power Analysis of Test Group Size 390
In previous experiments we observed that the incidence of EAE in adult cynomolgus macaques 391 of either sex is 95.45% as 21 out of 22 animals developed the disease following immunization 392 with rhMOG/IFA (unpublished results). This indicates that each animal has a theoretical 393 probability of 0.9545 to develop EAE under our protocol. For ethical motives and on behalf of 394 the 3 R principles (Replacement, Reduction and Refinement), we calculated the smallest possible 395 sample of macaques to prove the concept of therapeutic effectiveness of a molecule of which 396 biological significance had been previously measured over 12 macaques (Li et al, 2012) . We 397 used the Fisher Exact test to calculate the smallest possible sample to have no animal developing 398 the disease. As an acceptable level of confidence of 99% leads to a n = 3, we decided to perform 399 this preclinical study in 2 groups of 3 animals, either treated with anti-DC-ASGPR-MOG or anti-400 DC-ASGPR-PSA. In a successive experiment to check if intradermal injection of anti-DC-401 ASGPR-MOG induces anti-MOG IgG, only 2 animals were used. These were also exploited to 402 assess if pretreatment with anti-DC-ASGPR-MOG prevents rhMOG/IFA-induced EAE. associated to a rise of MOG-specific regulatory lymphocytes, which prevented lymphocyte 575 activation and the production of pro-inflammatory cytokines seen in control animals developing 576 an autoimmune encephalitis. Moreover, a significant upsurge of the anti-inflammatory cytokine 577 26 TGFb was observed after MOG re-immunization in animals receiving the effective treatment, 578 specifying the protective response elicited by the induced MOG-specific regulatory cells. 579
Impact: 580
Our experiments indicate that a vaccination scheme for immune tolerization towards a self-581 antigen is highly efficient in preventing autoimmune aggression in primates. This is notorious as 582 contrary to mouse strains, macaques are genetically diverse, indicating that the vaccine 583 efficiency is not restricted to a specific genotype and is the result of a general mechanism of 584 immune regulation. The results of this preclinical protocol raise great hopes for the treatment of 585 autoimmune conditions in humans through targeting of self-antigens to skin APC expressing 586 DC-ASGPR. Such treatment promises to be of easy administration, safe and highly efficient. 
